2 completed, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Arpida AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia iclaprim, vancomycin - Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia | Phase 2 | Terminated | Arpida AG | 135 | 2007-11-01 | 2009-02-13 |
| Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2) Intravenous iclaprim, Intravenous linezolid - Skin Diseases, Bacterial | Phase 3 | Completed | Arpida AG | 2006-03-01 | 2007-03-27 | |
| Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) intravenous iclaprim or intravenous linezolid - Complicated Skin and Skin Structure Infection | Phase 3 | Completed | Arpida AG | 2005-06-01 | 2008-04-04 |
Cellulitis (2) · Healthcare-Associated Pneumonia (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1) · Skin Diseases, Bacterial (1)
Vancomycin (1) · iclaprim (1)
United States (2)
David Willms, MD (1)